Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer
Abstract Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/21a72995ba6543e7a38aa0280d0ad7f4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:21a72995ba6543e7a38aa0280d0ad7f4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:21a72995ba6543e7a38aa0280d0ad7f42021-11-17T08:40:31ZPatient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer2198-384410.1002/advs.202101176https://doaj.org/article/21a72995ba6543e7a38aa0280d0ad7f42021-11-01T00:00:00Zhttps://doi.org/10.1002/advs.202101176https://doaj.org/toc/2198-3844Abstract Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers. PDOs are successfully generated from breast cancer tissues, including heavily treated specimens. The microtubule‐targeting drug‐sensitive response signatures of PDOs predict improved distant relapse‐free survival for invasive breast cancers treated with adjuvant chemotherapy. It is further demonstrated that PDO pharmaco‐phenotyping reflects the previous treatment responses of the corresponding patients. Finally, as clinical case studies, all patients who receive at least one drug predicate to be sensitive by PDOs achieve good responses. Altogether, the PDO model is developed as an effective platform for evaluating patient‐specific drug sensitivity in vitro, which can guide personal treatment decisions for breast cancer patients at terminal stage.Ping ChenXu ZhangRenbo DingLinglin YangXueying LyuJianming ZengJosh Haipeng LeiLijian WangJiong BiNan ShaoDitian ShuBin WuJingbo WuZhihui YangHaiyan WangBiqiong WangKang XiongYun LuShaozhi FuTak Kan ChoiNg Wai LonAiping ZhangDongyang TangYingyao QuanYa MengKai MiaoHeng SunMing ZhaoJiaolin BaoLei ZhangXiaoling XuYanxia ShiYing LinChuxia DengWileyarticleadvanced breast cancerdrug screeningpatient‐derived organoidspersonalized therapyScienceQENAdvanced Science, Vol 8, Iss 22, Pp n/a-n/a (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
advanced breast cancer drug screening patient‐derived organoids personalized therapy Science Q |
| spellingShingle |
advanced breast cancer drug screening patient‐derived organoids personalized therapy Science Q Ping Chen Xu Zhang Renbo Ding Linglin Yang Xueying Lyu Jianming Zeng Josh Haipeng Lei Lijian Wang Jiong Bi Nan Shao Ditian Shu Bin Wu Jingbo Wu Zhihui Yang Haiyan Wang Biqiong Wang Kang Xiong Yun Lu Shaozhi Fu Tak Kan Choi Ng Wai Lon Aiping Zhang Dongyang Tang Yingyao Quan Ya Meng Kai Miao Heng Sun Ming Zhao Jiaolin Bao Lei Zhang Xiaoling Xu Yanxia Shi Ying Lin Chuxia Deng Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer |
| description |
Abstract Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers. PDOs are successfully generated from breast cancer tissues, including heavily treated specimens. The microtubule‐targeting drug‐sensitive response signatures of PDOs predict improved distant relapse‐free survival for invasive breast cancers treated with adjuvant chemotherapy. It is further demonstrated that PDO pharmaco‐phenotyping reflects the previous treatment responses of the corresponding patients. Finally, as clinical case studies, all patients who receive at least one drug predicate to be sensitive by PDOs achieve good responses. Altogether, the PDO model is developed as an effective platform for evaluating patient‐specific drug sensitivity in vitro, which can guide personal treatment decisions for breast cancer patients at terminal stage. |
| format |
article |
| author |
Ping Chen Xu Zhang Renbo Ding Linglin Yang Xueying Lyu Jianming Zeng Josh Haipeng Lei Lijian Wang Jiong Bi Nan Shao Ditian Shu Bin Wu Jingbo Wu Zhihui Yang Haiyan Wang Biqiong Wang Kang Xiong Yun Lu Shaozhi Fu Tak Kan Choi Ng Wai Lon Aiping Zhang Dongyang Tang Yingyao Quan Ya Meng Kai Miao Heng Sun Ming Zhao Jiaolin Bao Lei Zhang Xiaoling Xu Yanxia Shi Ying Lin Chuxia Deng |
| author_facet |
Ping Chen Xu Zhang Renbo Ding Linglin Yang Xueying Lyu Jianming Zeng Josh Haipeng Lei Lijian Wang Jiong Bi Nan Shao Ditian Shu Bin Wu Jingbo Wu Zhihui Yang Haiyan Wang Biqiong Wang Kang Xiong Yun Lu Shaozhi Fu Tak Kan Choi Ng Wai Lon Aiping Zhang Dongyang Tang Yingyao Quan Ya Meng Kai Miao Heng Sun Ming Zhao Jiaolin Bao Lei Zhang Xiaoling Xu Yanxia Shi Ying Lin Chuxia Deng |
| author_sort |
Ping Chen |
| title |
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer |
| title_short |
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer |
| title_full |
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer |
| title_fullStr |
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer |
| title_full_unstemmed |
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer |
| title_sort |
patient‐derived organoids can guide personalized‐therapies for patients with advanced breast cancer |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://doaj.org/article/21a72995ba6543e7a38aa0280d0ad7f4 |
| work_keys_str_mv |
AT pingchen patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT xuzhang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT renboding patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT linglinyang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT xueyinglyu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT jianmingzeng patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT joshhaipenglei patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT lijianwang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT jiongbi patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT nanshao patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT ditianshu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT binwu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT jingbowu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT zhihuiyang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT haiyanwang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT biqiongwang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT kangxiong patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT yunlu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT shaozhifu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT takkanchoi patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT ngwailon patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT aipingzhang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT dongyangtang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT yingyaoquan patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT yameng patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT kaimiao patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT hengsun patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT mingzhao patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT jiaolinbao patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT leizhang patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT xiaolingxu patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT yanxiashi patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT yinglin patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer AT chuxiadeng patientderivedorganoidscanguidepersonalizedtherapiesforpatientswithadvancedbreastcancer |
| _version_ |
1718425657367592960 |